Brand GLP-1 prices collapsed in 2025–2026, making the gray market’s price advantage nearly irrelevant. In many cases, legitimate medications are now cheaper than research peptides of unknown purity.
| Channel | Monthly Cost | Safety | Details |
|---|---|---|---|
| With insurance + savings card | $25/mo | FDA-Approved | Wegovy and Zepbound copay cards cover most commercially insured patients. Many pay $0. |
| Medicare (mid-2026) | ~$50/mo | FDA-Approved | Cardiovascular indication coverage. Negotiated pricing under Medicare Part D. |
| Oral Wegovy | $149/mo | FDA-Approved | Pill form, no injections. Launched January 2026. Cash price. |
| Hims/Ro telehealth (brand) | $199–349/mo | Licensed | FDA-approved Wegovy via Novo Nordisk partnership. Includes physician consult. |
| LillyDirect Zepbound vials | $299/mo | FDA-Approved | Direct from Eli Lilly. 2.5mg single-dose vials. No middlemen. |
| NovoCare Wegovy cash | $349/mo | FDA-Approved | All doses. Introductory pricing: $199/mo for first 2 months. |
| Gray-market research vial | $40–150/mo | Unregulated | 7–14% actual purity. Endotoxin detected in 100% of samples tested. No recourse if harmed. |
In 2023, the price ratio between brand semaglutide ($1,000+/mo) and gray-market research peptides (~$40/mo) was roughly 25:1. That gap justified the risk for many people. Today the ratio is approximately 3.5:1 ($349 vs $100) at cash prices — and with manufacturer savings cards, legitimate GLP-1s are often cheaper than gray-market alternatives of unknown composition. The economic argument for research peptides has fundamentally collapsed.
We maintain a verified directory of FDA-approved GLP-1 telehealth providers, ranked by cost and transparency. Every provider prescribes brand medications through licensed physicians.
Find legitimate care